HIV-1 Vpr: Genetic diversity and functional features from the perspective of structure

DNA and Cell Biology

Volumn 23, Issue 4, 2004, Pages 207-222

  Tungaturthi, Parithosh K ^a   Sawaya, Bassel E ^b   Ayyavoo, Velpandi ^c   Murali, Ramachandran ^d   Srinivasan, Alagarsamy ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VPR PROTEIN;

CONFERENCE PAPER; DNA SEQUENCE; ENVELOPE GENE; GENE MUTATION; GENE STRUCTURE; GENETIC CONSERVATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN STRUCTURE; RETROVIRUS; RNA VIRUS; SEQUENCE ANALYSIS; STOP CODON; VIRAL GENETICS; VIRUS ENVELOPE; VIRUS GENOME; VIRUS ISOLATION; VIRUS VIRULENCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; APOPTOSIS; CELL CYCLE; GENE PRODUCTS, VPR; HIV-1; HUMANS; PROTEIN STRUCTURE, TERTIARY; TRANS-ACTIVATION (GENETICS); VARIATION (GENETICS);

DNA VIRUSES; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; UNIDENTIFIED RETROVIRUS;

EID: 2342637186     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454904773819798     Document Type: Conference Paper

References (158)

1. AGOSTINI, I., NAVARRO, J.M., REY, F., BOUHAMDAN, SPIRE, B., VIGNE, R., and SIRE, J. (1996). The human immunodeficiency virus type 1 Vpr transactivator: cooperation with promoter-bound activator domains and binding to TFIIB. J Mol Biol. 261, 599-606.
2. AGOSTINI, I., POPOV, S., HAO, T., LI, J.H., DUBROVSKY, L., CHAIKA, O., CHAIKA, N., LEWIS, R., and BUKRINSKY, M. (2002). Phosphorylation of Vpr regulates HIV type 1 nuclear import and macrophage infection. AIDS Res. Hum. Retroviruses 18, 283-288.
3. AHMAD, N., MATALA, E., YEDAVALLI, V.R.K., HAHN, T., and HUSAIN, M. (2000). Characterization of human immunodeficiency virus type 1 involved in maternal-fetal transmission. Adv. Anim. Virol. 1, 351-370.
4. ANDO, T., KAWABE, T., OHARA, H., DUCOMMUN, B., ITOH, M., and OKAMOTO, T. (2001). Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J. Biol. Chem. 276, 42971-42977.
5. ANTONI, B.A., SABBATINI, P., RABSON, A.B., and WHITE, E. (1995). Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection. J. Virol. 69, 2384-2392.
6. ARUNAGIRI, C., MACREADIE, I., HEWISH, D., and AZAD, A. (1997). A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochondrial dysfunction and apoptosis of human CD4+ lymphocytes. Apoptosis 2, 69-76.
7. AYYAVOO, V., MAHBOUBI, S., MAHALINGAM, S., RAMALINGAM, R., KUDCHODKAR, S., WILLIAMS, W.V., GREEN, D.R., and WINER, D.B. (1997a). HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat. Med. 3, 1117-1123.
8. AYYAVOO, V., MUTHUMANI, K., KUDCHODKAR, S., ZHANG, D., RAMANATHAN, P., DAYES, N.S., KIM, J.J., SIN, J.I., MONTANER, L.J., and WEINER, D.B. (2002). HIV-1 viral protein R compromises cellular immune function in vivo. Int. Immunol. 14, 13-22.
9. AYYAVOO, V., RAFAELI, Y., NAGASHUNMUGAM, T., MAHALINGAM, S., PHUNG, M., HAMAM, A., WILLIAMS, W.V., and WEINER, D.B. (1997b). HIV-1 viral protein R (Vpr) as a regulator of the target cell. Psychoneuroendoc. 22, S41-S49.
10. AZAD, A.A. (2000). Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells? Biochem. Biophys. Res. Commun. 267, 677-685.
11. BACHAND, F., YAO, X.J., HRIMECH, M., ROUGEAU, N., and COHEN, E.A. (1999). Incorporation of Vpr into human immunodeficiency virus type 1 requires a direct interaction with the p6 domain of the p55 gag precursor. J Biol Chem. 274, 9083-9091.
12. BALLIET, J.W., KOLSON, D.L., EIGER, G., KIM, F.A., MCGANN, K.A., SRINIVASAN, A. and COLLMAN, R. (1994). Distinct effects in primary macrophages and lymphocytes of human immunodeficiency virus type 1 accessory genes vpr, vpu and nef: Mutational analysis of a primary HIV-1 isolate. Virology 200, 623-631.
13. 2 accumulation by a mechanism which differs from DNA damage checkpoint control. J. Virol. 70, 2324-2331.
14. BOGERD, H.P., FRIDELL, R.A., BLAIR, W.S., and CULLEN, B.R. (1993). Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus. J. Virol. 67, 5030-5034.
15. BOUHAMDAN, M., BENICHOU, S., REY, F., NAVARRO, J.M., AGOSTINI, I., SPIRE, B., CAMONIS, J., SLUPPHAUG, G., VIGNE, R., BENAROUS, R., and SIRE, J. (1996). Human immunodeficiency virus type 1 Vpr protein binds to the uracil DNA glycosylase DNA repair enzyme. J Virol. 70, 697-704.
16. BOUHAMDAN, M., XUE, Y., BAUDAT, Y., HU, B., SIRE, J., POMERANTZ, R.J., and DUAN, L.X. (1998). Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins. J. Biol. Chem. 273, 8009-8016.
17. BUKRINSKY, M., and ADZHUBEI, A. (1999). Viral protein R of HIV-1. Rev. Med. Virol. 9, 39-49.
18. CARL, S., GREENOUGH, T.C., KRUMBIEGEL, M., GREENBERG, M., SKOWRONSKI, J. SULLIVAN, J.L., and KIRCHHOFF, F. (2001). Modulation of different human immunodeficiency virus type 1 Nef functions during progression of AIDS. J. Virol. 75, 3657-3665.
19. CENTERS FOR DISEASE CONTROL AND PREVENTION. (2000). HIV/AIDS surveillance report, vol. 12. Atlanta: CDC; pp. 1-44.
20. CHANG, L.J., CHEN, C.H., URLACHER, V., and LEE, T.Z. (2000). Differential apoptosis effects of primate lentiviral Vpr and Vpx in mammalian cells. J. Biomed. Sci. 7, 322-333.
21. CHECROUNE, F., YAO, X.J., GOTTLINGER, H., BERGERON, D., and COHEN, E.A. (1995). Incorporation of Vpr into human immunodeficiency virus type 1: Role of conserved regions within the P6 domain of Pr55gag. J. Acquired. Immune Defic. Syndr. 10, 1-7.
22. 2 arrest, nuclear localization, and cell death in fission yeast. J. Virol. 73, 3236-3245.
23. 2/M cell cycle arrest. Virology 305, 371-377.
24. COFFIN, J.M. (1995). HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science. 267, 483-489.
25. COHEN, E.A., DEHNI, G., SODROSKI, J.G., and HASELTINE, W.A. (1990a). Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J. Virol. 64, 3097-3099.
26. COHEN, E.A., TERWILLIGER, E.F., JALINOOS Y., PROULX, J., SODROSKI, J.G., and HASELTINE, W.A. (1900b). Identification of HIV-1 vpr product and function. J. Acquir. Immune Defic. Syndr. 3, 11-18.
27. COHEN, O.J., KINTER, A., and FAUCI, A.S. (1997). Host factors in the pathogenesis of HIV disease. Immunol Rev. 159, 31-48.
28. CONNOR, R.I., CHEN, B.K., CHOE, S., and LANDAU, N.R. (1995). Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206, 935-944.
29. CONTI, L., RAINALDI, G., MATARRESE, P., VERANO, B., RIVABENE, R., COLUMBA, S., SATO, A., BELARDELLI, F., MALORNI, W., and GESSANI, S. (1998). The HIV-1 Vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: Possible implications for the pathogenesis of AIDS. J. Exp. Med. 187, 403-413.
30. CONTI, L., MATARRESE, P., VARANO, P., GAUZZI, M.C., SATO, A., MALORNI, W.A., BELARDELLI, F., and GESSANI, S. (2000). Dual role of the HIV-1 vpr protein in the modulation of the apoptotic response of T cells. J. Immunol. 165, 3293-3300.
31. CULLEN, B.R. (1988). HIV-1 auxillary proteins: Making connections in a dying cell. Cell 93, 685-692.
32. DE NORONHA, C.M., SHERMAN, M.P., LIN, H.W., CAVROIS, M.V., MOIR, R.D., GOLDMAN, R.D., and GREENE, W.C. (2001). Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294, 1105-1108.
33. DE ROCQUIGNY, H., PETITJEAN, P., TANCHOU, V., DECIMO, D., DROUOT, L., DELAUNAY, T., DARLIX, J.L., and ROQUES, B.P. (1997). The zinc fingers of HIV nucleocapsid protein NCp7 direct interactions with the viral regulatory protein Vpr. J. Biol. Chem. 272, 30753-30759.
34. DI MARZIO, P., CHOE, S., EBRIGHT, M., KNOBLAUCH, R., and LANDAU, N.R. (1995). Mutational analysis of cell cycle arrest, nuclear localization, and virion packaging of human immunodeficiency virus type 1 Vpr. J. Virol. 69, 7909-7916.
35. EMERMAN, M. (1996). HIV-1 Vpr and the cell cycle. Curr. Biol. 6, 1096-1103.
36. EMERMAN, M., and MALIM, M.H. (1998). HIV-1 regulatory/accessory genes: Keys to unravelling viral and host cell biology. Science. 280, 1880-1884.
37. ENGLER, A., STANGLER, T., and WILLBOLD, D. (2002). Structure of human immunodeficiency virus type 1 Vpr(34-51) peptide in micelle containing aqueous solution. Eur. J. Biochem. 269, 3264-3269.
38. FANALES-BELASIO, E., CAFARO, A., CARA, A., NEGRI, D.R., FIORELLI, V., BUTTO, S., MORETTI, S., MAGGIORELLA, M.T., BARONCELLI, S., MICHELINI, Z., et al. (2002). HIV-1 Tat-based vaccines: From basic science to clinical trials [Review]. DNA Cell Biol. 21, 599-610.
39. FELZIEN, L.K., WOFFENDIN, C., HOTTIGER, M.O., SUBBRAMANIAN, R.A., COHEN, E.A., and NABEL, G.J. (1998). HIV transcriptional activation by the accessory protein, Vpr, is mediated by the p300 co-activator. Proc Natl Acad Sci USA. 95, 5281-5286.
40. FORGET, J., YAO, X.J., MERCIER, J., and COHEN, E.A. (1998). Human immunodeficiency virus type 1 Vpr protein transactivation function: Mechanism and identification of domains involved. J. Mol. Biol. 284, 915-923.
41. FOUCHIER, R.A.M., MEYER, B.E., SIMON, J.H.M., FISCHER, U., ALBRIGHT, A.V., GONZALESZ-SCARANO, F., and MALIM, M.M. (1998). Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J. Viol. 72, 6004-6013.
42. FUKUMORI, T., AKAMI, H., IIDA, S., HATA, S., KAGAWA, S., AIDA, Y., KOYANA, A.H., and ADACHI, A. (1998). The HIV-1 Vpr displays strong anti-apoptotic activity. FEBS Lett. 432, 17-20.
43. GASCHEN, B., TAYLOR, J., YUSIM, K., FOLEY, B., GAO, F., LANG, D., NOVITSKY, D., HAYNES, B., HAHM, B.H., BATTACHARYA, T., et al. (2002). Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360.
44. GAYNOR, E.M., and CHEN, I.S. (2001). Analysis of apoptosis induced by HIV-1 Vpr and examination of the possible role of the hHR23A protein. Exp. Cell Res. 267, 243-257.
45. GE, Y.C., WANG, B., DEVYER, D.E., CUNNINGHAM, A.L., and SAKSENA, N.K. (1996). Length polymorphism of the viral protein R of human immunodeficiency virus type 1 strains. AIDS Res. Hum. Retroviruses. 12, 351-354.
46. GOH, W.C., ROGEL, M.E., KINSEY, C.M., MICHAEL, S.F., FULTZ, P.N., NOWAK, M.A., HAHN, B.H., and EMERMAN, M. (1998). HIV-1 Vpr increases viral expression by manipulation of the cell cycle - A mechanism for selection of Vpr in vivo. Nat. Med. 4, 65-71.
47. GRAGEROV, A., KINO, T., IIYINA-GRAGEROVA, G., CHROUSOS, G.P., and PAVLAKIS, G.N. (1998). HHR23A, the human homologue of the yeast repair protein RAD23, interacts specifically with Vpr protein and prevents cell cycle arrest but not the transcriptional effects of Vpr. Virology 245, 323-330.
48. GUMMULURU, S., and EMERMAN, M. (1999). Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J. Virol. 73, 5422-5430.
49. 2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69, 6705-6711.
50. HEINZINGER, N.K., BUKINSKY, M.I., HAGGERTY, S.A., RAGLAND, A.M., KEWALRAMANI, LEE, M.V., GENDELMAN, H.E., RATNER, L., STEVENSON, M., and EMERMAN, M. (1994). The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in non-dividing host cells. Proc. Natl. Acad. Sci. USA 91, 7311-7315.
51. 2 cell cycle arrest. J. Biol. Chem. 275, 32016-32026.
52. HERBEIN, G., VAN LINT, C., LOVETT, J., and VERDIN, E. (1998). Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1 - Infected and in uninfected bystander T lymphocytes. J. Virol. 72, 660-670.
53. HO, D.D., NEUMANN, A.U., and PERELSON, A.S. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
54. HOGAN, T.H., NONNEMACHER, M.R., KREBS, F.C., HENDERSON, A., and WIGDAHL, B. (2003). HIV-1 Vpr binding to HIV-1 LTR C/EBS cis-acting elements and adjacent regions is sequence-specific. Biomed. Pharmacother. 57, 41-48.
55. HRIMECH, M., YAO, X.-J., BACHAND, F., ROUGEAU, N., and CHEN, E.A. (1999). Human immunodeficiency virus type 1 Vpr functions as an immediate-early protein during HIV-1 function. J. Virol. 73, 4101-4109.
56. HUANG, M.B., WEEKS, O., ZHAO, L.J., SALTARELLI, M., and BOND, V.J. (2000). Effects of extracellular human immunodeficiency virus type 1 vpr protein in primary rat cortical cell cultures. J. Neurovirol. 6, 202-220.
57. JACOTOT, E., RAVAGNAN, L., LOEFFLER, M., FERRI, K.F., VIEIRA, H.L., ZAMZAMI, N., COSTANTINI, P., DRUILLENNEC, S., HOEBEKE, J., BRIAND, J.P., et al. (2000). The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. J. Exp. Med. 191, 33-46.
58. JOWETT, J.B., XIE, Y.-M., and CHEN, I.S.Y. (1999). The presence of human immunodeficiency virus type 1 Vpr correlates with a decrease in the frequency of mutations in a Plasmid Shuttle Vector. J. Virol. 73, 7132-7137.
59. 2 + M phase of the cell cycle. J. Virol. 69, 6304-6313.
60. KAMATA, M., and AIDA, Y. (2000). Two putative alpha-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms. J. Virol. 74, 7179-7186.
61. KINO, T., GRAGEROV, A., KOPP, J.B., STAUBER, R.H., PAVLAKIS, G.N., and CHROUSOS, G.P. (1999). The HIV-1 virion-associated protein Vpr is a coactivator of the human glucocorticoid receptor. J. Exp. Med. 189, 51-61.
62. KINO, T., GRAGEROV, A., SLOBODSKAYA, O., TSOPANOMICHALOU, M., CHROUSOS, G.P., and PAVLAKIS, G.N. (2002a). Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J. Virol. 76, 9724-9734.
63. KINO, T., TSUKAMOTO, M., and CHROUSOS, G.P. (2002b). Transcription factor TFIIH components enhance the GR coactivator activity but not the cell cycle-arresting activity of the human immunodeficiency virus type-1 protein Vpr. Biochem. Biophys. Res. Commun. 298, 17-23.
64. KNIPE, D.M., and HOWLEY, P.M. (2001). Fields virology, vols. 1 and 2, 4th ed. Philadelphia: Lippincott-Raven.
65. KOBINGER, G.P., BORSETTI, A., NIE, Z., MERCIER, J., DANIE, L.N., GOTTLINGER, H.G., and COHEN, E.A. (1998). Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins. J. Viol. 72, 5441-5448.
66. KONDO, E., and GOTTLINGER, H.G. (1996). A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr. J. Virol. 70, 159-164.
67. KONDO, E., MAMMANO, F., COHEN, E.A., and GOTTLINGER, H.G. (1995). The p6 gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous virus particles. J. Virol. 69, 2759-2764.
68. KUIKEN, C., FOLEY, B., HAHN, B., MARX, P., MCCUTCHAN, F., MELLORS, J., MULLINS, J., WOLINSKY, S., and KORBER, B. (1999). Human Retroviruses and AIDS (Los Alamos National Lab., Los Alamos, NM).
69. KUIKEN, C.L., CORNELISSEN, M.T.E., ZORGDRAGER, F., HARTMAN, S., GIBBS, A.J., and GOUDSMIT, J. (1996). Consistent risk group associated differences in human immunodeficiency virus type 1 Vpr, Vpu, and v3 sequences despite independent evolution. J. Gen. Virol. 77, 780-792.
70. LAI, D., SINGH, S.P., CARTAS, M., MURALI, R., KALYANARAMAN, V.S., and SRINIVASAN, A. (2000). Extent of incorporation of HIV-1 Vpr into the virus particles is flexible and can be modulated by expression level in cells. FEBS Lett. 469, 191-195.
71. LE ROUZIC, E., MOUSNIER, A., RUSTUM, C., STUTZ, F., HALLBERG, E., DARGEMONT, C., and BENICHOU, S. (2002). Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J. Biol. Chem. 277, 45091-45098.
72. LETVIN, N.L., and WALKER, B.D. (2003). Immunopathogenesis and immunotherapy in AIDS virus infections. Nat. Med. 9, 861-866.
73. LEVY, D.N., FERNANDES, L.S., WILLIAMS, W.V., and WEINER, D.B. (1993). Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72, 541-550.
74. LEVY, D.N., RAFAELI, Y., MACGREGOR, R.R., and WEINER, R. (1994). Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 91, 10873-10877.
75. LEVY, D.N., RAFAELI, Y., and WEINER, D.B. (1995). Extracellular vpr protein increases cellular permissiveness of human immunodeficiency virus replication and reactivates virus from latency. J. Virol. 69, 1243-1252.
76. LEVY, J.A. (1998). HIV and the pathogenesis of AIDS. (ASM Press, Washington, DC).
77. LI, M.S., GARCIA-ASUA, G., BHATTACHARYYA, U., MASCAGNI, P., AUSTEN, B.M., and ROBERTS, M.M. (1996). The Vpr protein of human immunodeficiency virus type 1 binds to nucleocapsid protein p7 in vitro. Biochem. Biophys. Res. Commun. 218, 352-355.
78. LU, Y.-L., BENNETT, R.P., WILLS, J.W., GORELICK, R., and RATNER, L. (1995). A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J. Virol. 69, 6873-6879.
79. LU, Y.L., SPEARMAN, P., and RATNER, L. (1993) Human immunodeficiency virus type 1 viral protein R localization in infected cells and virions. J. Virol. 67, 6542-6550.
80. LUM, J.J., COHEN, O.J., NIE, Z., WEAVER, J.G., GOMEZ, T.S., YAO, X.J., LYNCH, D., PILON, A.A., HAWLEY, N., KIM, J.E., et al. (2003) Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. J. Clin. Invest. 111, 1547-1554.
81. LUO, Z., BUTCHER, D.J., MURALI, R., SRINIVASAN, A., and HUANG, Z. (1998). Structural studies of synthetic peptide fragments derived from the HIV-1 Vpr protein. Biochem. Biophys. Res. Commun. 244, 732-736.
82. MACREADIE, I.G., CASTELLI, L.A., HEWISH, D.R., KIRKPATRICK, A., WARD, A.C., and AZAD, A.A. (1995). A domain of human immunodeficiency virus type-1 Vpr containing repeated H(S/F)RIG amino acid causes cell growth arrest and structural defects. Proc. Natl. Acad. Sci. USA 92, 2770-2774.
83. MAHALINGAM, S., AYYAVOO, V., PATEL, M., KIEBER-EMMONS, T., and WEINER, D.B. (1997a). Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J. Virol. 71, 6339-6347.
84. MAHALINGAM, S., COLLMAN, R.G., MONKEN, C.E., PATEL, M., and SRINIVASAN, A. (1995c). Role of conserved dipeptide Gly(75) and Cys(76) on HIV-1 Vpr function. Virology 212, 331-339.
85. MAHALINGAM, S., COLLMAN, R.G., PATEL, M., MONKEN, C.E., and SRINIVASAN, A. (1995a). Functional analysis of HIV-1 Vpr: Identification of determinants essential for subcellular localization. Virology 212, 313-339.
86. MAHALINGAM, S., KHAN, S.A., JABBAR, M.A., MONKEN, C.E., COLLMAN, R., and SRINIVASAN, A. (1995d). Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation. Virology 207, 297-302.
87. MAHALINGAM, S., KHAN, S.A., MURALI, R., JABBAR, M.A., MONKEN, C.E., COLLMAN, R., and SRINIVASAN, A. (1995e). Mutagenesis of the putative a-helical domain of the Vpr protein of human immunodeficiency virus type 1: Effect on stability and virion incorporation. Proc. Natl. Acad. Sci. USA 92, 3794-3798.
88. MAHALINGAM, S., MACDONALD, B., UGEN, K.E., AYYAVOO, V., AGADJAYAN, M.G., WILLIAMS, W.V., and WEINER, D.B. (1997b). In vitro and in vivo tumor growth suppression by HIV-1 Vpr. DNA Cell Biol. 16, 137-143.
89. MAHALINGAM, S., PATEL, M., COLLMAN, R.G., and SRINIVASAN, A. (1995b). The carboxy terminal domain is essential for stability and not for virion incorporation of HIV-1 Vpr into virus particles. Virology 214, 647-652.
90. MALIM, M.H., and EMERMAN, M. (2001). HIV-1 sequence variation: Drift, shift, and attenuation. Cell 104, 469-472.
91. MANSKY, L.M. (1996). The mutation rate of human immunodeficiency virus type 1 is influenced by the vpr gene. Virology 222, 391-400.
92. MANSKY, L.M., PREVERAL, S., SELIG, L., BENAROUS, R., and BENICHOU, S. (2000). The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. J. Virol. 74, 7039-7047.
93. MASUDA, M., NAGAI, Y., OSHIMA, N., TANAKA, K., MURAKAMI, H., IGARASHI, H., and OKAYAMA, H. (2000). Genetic studies with the fission yeast Schizosaccharomyces pombe suggest involvement of wee1, ppa2, and rad24 in induction of cell cycle arrest by human immunodeficiency virus type 1 Vpr. J. Virol. 74, 2636-2646.
94. MCCUNE, J.M. (1995). Viral latency in HIV disease. Cell 82, 183-188.
95. MICHAEL, N.L., CHANG, G., D'ARCY, L.A., EHRENBERG, P.K., MARIANI, R., BUSEN, M.P., BRIX, D.L., and SCHWARTZ, D.H. (1995). Defective accessory genes in a human immunodeficiency virus type 1 infected long-term survivor lacking recoverable virus. J. Virol. 69, 4228-4236.
96. MORELLET, N., BOUAZIZ, S., PETITJEAN, P., and ROQUES, B.P. (2003). NMR structure of the HIV-1 regulatory protein VPR. J. Mol. Biol. 327, 215-227.
97. MULLER, B., TESSMER, U., SCHUBERT, U., and KRAUSSLICH, H.G. (2000). Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells. J. Virol. 74, 9727-9731.
98. MUTHUMANI, K., CHOO, A.Y., CHATTERGOON, D.S., DAYES, N.N., ZHANG, D., LEE, M.D., DUVVURI, U., and WEINER, D.B. (2003). Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem. Biophys. Res. Commun. 304, 583-592.
99. MUTHUMANI, K., HWANG, D.S., DESAI, B.M., ZHANG, D., DAYES, N., GREEN, D.R., and WEINER, D.B. (2002). HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J. Biol. Chem. 277, 37820-37831.
100. NAKAMURA, T., SUZUKI, H., OKAMOTO, T., KOTANI, S., ATSUJI, Y., TANAKA, T., and ITO, Y. (2002). Recombinant Vpr (rVpr) causes augmentation of HIV-1 p24 Ag level in U1 cells through its ability to induce the secretion of TNF. Virus Res. 90, 263-268.
101. NEI, Z., BERGERON, D., SUBBRAMANIAN, R.A., YAO, X.-J., CHECROUNE, F., ROUGEAU, N., and COHEN, E.A. (1998). The putative alpha helix 2 of human immunodeficiency virus type 1 Vpr contains a determinant which is responsible for the nuclear translocation of proviral DNA in growth-arrested cells. J. Virol. 72, 4104-4115.
102. PATEL, C.A., MUKHTAR, M., and POMERANTZ, R.J. (2000). Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J. Virol. 74, 9717-9726.
103. PAXTON, W., CONNOR, R.I., and LANDAU, N.R. (1993). Incorporation of Vpr into human immunodeficiency virus type 1 virions: Requirement for the p6 region of gag and mutational analysis. J. Virol. 67, 7229-7237.
104. PERSAUD, D., ZHOU, Y., SILICIANO, J.M., and SILICIANO, R.F. (2003). Latency in human immunodeficiency virus type 1 infection: No easy answers. J. Virol. 77, 1659-1665.
105. PILLER, S.C., EDWART, G.D., JANS, D.A., GAGE, W., and COX, G.B. (1999). The amino-terminal region of Vpr from Human Immunodeficiency Virus type 1 forms ion channels and kills neurons. J. Virol. 73, 4230-4238.
106. PILLER, S.C., EWART, G.D., PREMKUMAR, A., COX, G.B., and GAGE, P.W. (1996). Vpr protein of human immunodeficiency virus type 1 forms cation selective channels in planar lipid bilayers. Proc. Natl. Acad. Sci. USA 93, 111-115.
107. POLI, G., and FAUCI, A.S. (1992). The role of monocytes/macrophages and cytokines in the pathogenesis of human immunodeficiency virus infection. Pathobiology 60, 246-251.
108. POON, B., GROVIT-FEERBAS, K., STEWART, S.A., and CHEN, I.S.Y. (1998). Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science 281, 266-269.
109. POPOV, S., REXACH, M., RATNER, L., BLOBEL, G., and BUKRINSKY, M. (1998a). Viral Protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J. Biol. Chem. 273, 13347-13352.
110. POPOV, S., REXACH, M., ZYRBATH, G., REILING, V., LEE, M.A., RANER, L., LANE, M.A., MOORE, M.S., BLODEL, G., and BUKRINSKY, M. (1998b). Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. EMBO J. 17, 909-917.
111. RAPPAPORT, J. (2003). Perspectives in HIV pathogenesis, treatment, and prevention. Biomed. Pharmacother. 57, 1-3.
112. 2 by inhibiting the activation of p34cdc2-cyclin B. J. Virol. 69, 6859-6864.
113. REFAELI, Y., LEVY, D.N., and WEINER, D.B. (1995). The glucocorticoid receptor type II complex is a target of the HIV-1 Vpr gene product. Proc. Natl. Acad. Sci. USA 92, 3621-3625.
114. ROGEL, M.E., WU, L.I., and EMERMAN, M. (1995). The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J. Virol. 69, 882-888.
115. ROUX, P., ALFIERIC, C., HRIMECH, M., COHEN, E.A., and TANNER, J.E. (2000). Activation of transcription factors NF-kappaB and NF-IL-6 by human immunodeficiency virus type 1 protein R (Vpr) induces interleukin-8 expression. J. Virol. 74, 4658-4665.
116. SAKSENA, N.K., GE, Y.C., WANG, B., PALASANTHIRAM, P., XIANG, S.H., DWYER, D.E., RANDLE, C., ZIEGLER, J., and CUNNINGHAM, A.L. (1996). An HIV-1 infected long-term nonprogressor (LTNP): Molecular analysis of HIV-1 strains in the Vpr and Nef genes. Ann. Acad. Med. Singapore 25, 848-854.
117. SATO, A., YOSHIMOTO, J., ISAKA, Y., MIKI, S., SUYAMA, A., HAYAMI, M., FUJIWARA, T., and YOSHIE, O. (1996). Evidence for direct association of Vpr and Matrix protein p17 within the HIV-1 virion. Virology 220, 208-212.
118. SAWAYA, B.E., KHALILI, K., GORDON, J., SRINIVASAN, A., RICHARDSON, M., RAPPAPORT, J., and AMINI, S. (2000). Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73. J. Virol. 74, 4877-4881.
119. SAWAYA, B.E., KHALILI, K., MERCER, W.E., DENISOVA, L., and AMINI, S. (1998). Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription. J. Biol. Chem. 273, 20052-20057.
120. SCHULER, W., WECKER, K., DE ROCQUIGNY, H., BAUDAT, Y., SIRE, J., and ROQUES, B.P. (1999). NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: Molecular insights into its biological functions. J. Mol. Biol. 285, 2105-2117.
121. SELIG, L., PAGES, J.-C., TANCHOU, V., PREVERAL, S., BERLIOZ-TORRENT, C., LIU, L.X., ERDTMANN, L., DARLIX, J.-L., BENAROUS, R., and BENICHOU, S. (1999). Interaction with the p6 domain of the Gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses. J. Virol. 73, 592-600.
122. SHERMAN, M.P., DE NORONHA, C.M., PEARCE, D., and GREENE, W.C. (2000). Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest. J. Virol. 74, 8159-8165.
123. SHERMAN, M.P., SCHUBERT, U., WILLIAMS, S.A., DE NORONHA, C.M., KREISBERG, J.F., HENKLEIN, P., and GREENE, W.C. (2002). HIV-1 Vpr displays natural protein-transducing properties: Implications for viral pathogenesis. Virology 302, 95-105.
124. SINGH, S.P., LAI, D., CARTAS, M., SERIO, D., MURALI, R., KALYANARAMAN, V.S., and SRINIVASAN, A. (2000a). Epitope-tagging approach to determine the stoichiometry of the structural and nonstructural proteins in the virus particles: Amount of Vpr in relation to Gag in HIV-1. Virology 268, 364-371.
125. SINGH, S.P., TOMKOWICZ, B., LAI, D., CARTAS, M., MAHALINGAM, S., KALYANARAMAN, V.S., MURALI, R., and SRINIVASAN, A. (2000b). Functional role of residues corresponding to helical domain II (amino Acids 35 to 46) of human immunodeficiency virus type 1 Vpr. J. Virol. 74, 10650-10657.
126. SINGH, S.P., TUNGATURTHI, P., CARTAS, M., TOMKOWICZ, B., RIZVI, T.A., KHAN, S.A., KALYANARAMAN, V.S., and SRINIVASAN, A. (2001). Virion-associated HIV-1 Vpr: Variable amount in virus particles derived from cells upon virus infection on proviral DNA transfection. Virology 283, 78-83.
127. SOMASUNDARAN, M., SHARKEY, M., BRICHACEK, B., LUZURIAGA, K., EMERMAN, M., SULLIVAN, J.L., and STEVENSON, M. (2002). Evidence for a cytopathogenicity determinant in HIV-1 Vpr. Proc. Natl. Acad. Sci. USA 99, 9503-9508.
128. STARK, L.A., and HAY, R.T. (1998). Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) interacts with Lys-tRNA synthetase: Implications for priming of HIV-1 reverse transcription. J. Virol. 72, 3037-3044.
129. STEWART, S.A., POON, B., JOWET, J.B., and CHEN, I.S. (1997). Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J. Virol. 71, 5579-5592.
130. STEWART, S.A., POON, B., JOWETT, J.B., XIE, Y., and CHEN, I.S. (1999). Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc. Natl. Acad. Sci. USA. 96, 12039-12043.
131. STEWART, S.A., POON, B., SONG, J.Y., and CHEN, I.S. (2000). Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J. Virol. 74, 3105-3111.
132. SUBBRAMANIAN, R.A., KESSOUS-ELBAZ, A., LODGE, R., FORGET, J., YAO, X.J., BERGERON, D., and COHEN, E.A. (1998a). Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J. Exp. Med. 187, 1103-1111.
133. SUBBRAMANIAN, R.A., YAO, X.J., DILHUYDY, H., ROUGEAU, N., BERGERON, D., ROBITALLE, Y., and COHEN, E.A. (1998b). Human immunodeficiency virus type 1 Vpr localization: Nuclear transport of a viral protein modulated by a putative amphipathic helical structure and its relevance to biological activity. J. Mol. Biol. 278, 13-30.
134. TUNGATURTHI, P.K., SAWAYA, B.E., SINGH, S.P., TOMKOWICZ, B., AYYAVOO, V., KHALILI, K., COLLMAN, R.G., AMINI, S., and SRINIVASAN, A. (2003). Role of HIV-1 Vpr in AIDS pathogenesis: Relevance and implications of intravirion, intracellular and free Vpr. Biomed. Pharmacother. 57, 20-24.
135. UNAIDS JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS. (2000). AIDS epidemic update: December. Geneva: UNAIDS.
136. VANITHARANI, R., MAHALINGAM, S., RAFAELI, Y., SINGH, S.P., SRINIVASAN, A., WEINER, D.B., and AYYAVOO, V. (2001). HIV-1 Vpr transactivates LTR-directed expression through sequences present within -278 to -176 and increases virus replication in vitro. Virology 289, 334-342.
137. VODICKA, M.A., KOEPP, D.M., SILVER, P.A., and EMERMAN, M. (1998). HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genet. Dev. 12, 17-185.
138. WANG, B., GE, Y.C., PALASANTHIRAN, P., XIANG, S.H., ZIEGLER, J., DWYER, D.E., RANDLE, C., DOWTON, D., CUNNINGHAM, A., and SAKSENA, N.K. (1996). Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: In vivo evolution of vpr quasispecies in blood and plasma. Virology 223, 224-232.
139. WANG, L., MUKHERJEE, S., JIA, F., NARAYAN, O., and ZHAO, L.J. (1995). Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J. Biol. Chem. 270, 25564-25569.
140. WECKER, K., and ROQUES, B.P. (1999). NMR structure of the (1-51) N-terminal domain of the HIV-1 regulatory protein Vpr. Eur. J. Biochem. 266, 359-369.
141. 2O/ trifluoroethanol. Eur. J. Biochem. 269, 3779-3788.
142. WEI, X., GHOSH, S.K., TAYLOR, M.E., JOHNSON, V.A., EMINI, E.A., DEUTSCH, P., LIFSON, J.D., BONHOEFFER, S., NOWAK, M.A., HAHN, B.H., et al. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
143. WEISS, R.A. (2003). HIV and AIDS: Looking ahead. Nat. Med. 9, 887-891.
144. WESTERVELT, P., HENKEL, T., TROWBRIDGE, D.B., ORENSTEIN, J., HEUSER, J., GENDELMAN, H.E., and RATNER, L. (1992). Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants. J. Virol. 66, 3925-3931.
145. WITHERS-WARD, E.S., JOWETT, J.M.B., STEWART, S.A., XIE, Y.M., GARFINKEL, A., SHIBAGAKI, Y., CHOW, S.A., SHAH, N., HANNAOKA, F., SAWITZ, D.G., et al. (1997). Human immunodeficiency virus type 1 Vpr interacts with HHR23A. A cellular protein implicated in nucleotide excision DNA repair. J. Virol. 71, 9732-9742.
146. YAMADA, T., and IWAMOTO, A. (2000). Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch. Virol. 145, 1021-1027.
147. YAO, X., MOULAND, A.J., SUBBRAMANIAN, R.A., FORGET, J., ROUGEAU, N., BERGERON, D., and COHEN, E.A. (1998). Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing jurkat T cells. J. Virol. 72, 4686-4693.
148. YAO, X., SUBBRAMANIAN, R.A., ROUGEAU, N., BOISVERT, F., BERGERON, D., and COHEN, E.A. (1995). Mutagenic analysis of human immunodeficiency virus type 1 Vpr: Role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J. Virol. 69, 7032-7044.
149. YASUDA, J., MIYAO, T., KAMATA, M., AIDA, Y., and IWAKUSA, Y. (2001). T cell apoptosis causes peripheral T cell depletion in mice transgenic for the HIV-1 Vpr gene. Virology 285, 181-192.
150. YEDAVALLI, V.R.K., and AHMAD, N. (2001). How conservation of functional domains of HIV-1 Vif and Vpr genes in infected mother correlates with lack of vertical transmission. AIDS Res. Hum. Retroviruses 17, 911-923.
151. YEDAVALLI, V.R.K., CHAPPEY, C., and AHMAD, N. (1998). Maintenance of an intact human immunodeficiency virus type 1 Vpr gene following mother-to-infant transmissino. J. Virol. 72, 6937-6943.
152. YONCHU, J., PORNILLOS, O., RICH, R.L., MYSZKA, D.G., SUNDQUIST, W.I., and MALIM, M.H. (2001). Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6Gag. J. Virol. 75, 10537-10542.
153. ZANDER, K., SHERMAN, M.P., TESSMER, U., BRUNS, K., WRAY, V., PRETCHEL, A.T., SCHUBERT, E., HENKLEIN, P., LUBAN, J., NEIDLEMAN, J., et al. (2003). Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression. J. Biol. Chem. 278, 43202-43213.
154. ZHANG, L., HUANG, Y., YUAN, H., TUTTLETON, S., and HO, D.D. (1997). Genetic characterization of Vif, Vpr and Vpu sequences from long-term survivors of human immunodeficiency virus type 1 infection. Virology 228, 340-349.
155. ZHAO, L.-J., MUKHERJEE, S., and NARAYAN, O. (1994a). Biochemical mechanism of HIV-1 Vpr function: Specific interaction with a cellular protein. J. Biol. Chem. 269, 15577-15582.
156. ZHAO, L.-J., WANG, L., MUKHERJEE, S., and NARAYAN, O. (1994b). Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J. Biol. Chem. 269, 32131-32137.
157. ZHOU, Y., and RATNER, L. (2000). Phosphorylation of human immunodeficiency virus type 1 Vpr regulates cell cycle arrest. J. Virol. 74, 6520-6527.
158. ZHOU, Y., LU, Y., and RATNER, L. (1998). Arginine residues in the C-terminus of HIV-1 Vpr are important for nuclear localization and cell cycle arrest. 242, 414-424.